Insulet Co. (NASDAQ:PODD) has received a consensus recommendation of “Buy” from the fourteen research firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $109.73.
A number of equities research analysts recently weighed in on the company. ValuEngine raised Insulet from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 18th. UBS Group raised their price objective on Insulet from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. BidaskClub downgraded Insulet from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. Northland Securities downgraded Insulet from an “outperform” rating to a “market perform” rating and set a $100.00 price objective on the stock. in a research report on Monday, June 10th. Finally, Piper Jaffray Companies raised their price objective on Insulet from $110.00 to $130.00 and gave the company a “positive” rating in a research report on Friday.
In other Insulet news, COO Charles Alpuche sold 3,900 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $104.78, for a total value of $408,642.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David A. Lemoine sold 8,752 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $106.92, for a total value of $935,763.84. Following the completion of the sale, the director now directly owns 9,148 shares of the company’s stock, valued at approximately $978,104.16. The disclosure for this sale can be found here. In the last three months, insiders sold 49,289 shares of company stock valued at $5,225,737. Corporate insiders own 3.50% of the company’s stock.
Shares of Insulet stock traded up $2.77 during trading on Friday, hitting $119.38. 564,472 shares of the stock traded hands, compared to its average volume of 580,889. The stock has a market cap of $6.96 billion, a price-to-earnings ratio of 2,387.60 and a beta of 1.13. The company has a current ratio of 4.36, a quick ratio of 3.71 and a debt-to-equity ratio of 2.68. Insulet has a 52-week low of $70.80 and a 52-week high of $122.19. The firm’s fifty day moving average is $110.99.
Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 EPS for the quarter, beating the consensus estimate of $0.02 by $0.05. Insulet had a return on equity of 7.01% and a net margin of 2.37%. The firm had revenue of $159.56 million for the quarter, compared to analyst estimates of $154.66 million. During the same quarter last year, the firm posted ($0.11) earnings per share. The business’s revenue for the quarter was up 29.1% on a year-over-year basis. On average, equities research analysts anticipate that Insulet will post 0.27 earnings per share for the current fiscal year.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Featured Article: Why is cost of goods sold important?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.